NEWS
2025114
PR Notice Regarding Completion of 30-Day Review for Clinical Trial Notification for Phase I/II Study of Cardiac Remuscularization Therapy HS-005 (Catheter Administration) Targeting Severe Heart Failure
2025911
PR Notice Regarding the New Partner for Delivery Catheter System for Allogeneic iPS Cell-Derived Cardiomyocyte Spheroids
2025414
Congress Keiichi Fukuda, CEO, to Speak at the 25th World Congress of the International Society for Heart Research (ISHR)
2025313
Other Heartseed has started CEO column, "TOP MESSAGE", on Investor Relation section of its website.
202523
PR Heartseed Announces Enrollment Completion in Phase 1/2 Clinical Trial using HS-001, an Investigational Stem Cell-Derived Therapy for Advanced Heart Failure